Adenovirus-mediated expression of dominant negative c-myb induces apoptosis in head and neck cancer cells and inhibits tumor growth in animal model.

The recent demonstration of aberrant expression of the c-myb proto-oncogene in various cancers suggests that c-myb plays an important role in the development of cancer. On this basis, it has been proposed that ablation of c-myb function might be an effective approach for therapy of c-myb dependent malignancies. We previously used a dominant negative c-myb (DN-myb) construct to induce apoptosis in K562 cells. In this study, DN-myb was expressed in an adenovirus-mediated gene delivery system and introduced into head and neck squamous cell carcinoma cells (HNSCC) in vitro and in vivo to examine its tumor suppressive function and its potential in HNSCC gene therapy. Over expression of DN-myb in HNSCC cells inhibited in vitro cell proliferation, expression of growth factors such as IGF-I, -II, IGF-1R, and VEGF, inhibited Akt/PKB pathway activation, and enhanced induction of apoptosis. Similarly, in vivo administration of DN-myb retarded tumor-growth. Our results support a role for DN-myb in inducing apoptosis and tumor suppression, and, furthermore, suggest that DN-myb gene therapy might provide a powerful tool for treatment of c-myb dependent malignancies such as HNSCC.

[1]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[2]  R. Rosenberg,et al.  c‐Myb function in fibroblasts , 1997, Journal of cellular physiology.

[3]  D. L. Sokol,et al.  Nucleic acid therapeutics: state of the art and future prospects. , 1998, Blood.

[4]  K. Weston.  Myb proteins in life, death and differentiation. , 1998, Current opinion in genetics & development.

[5]  M. Arsura,et al.  The myb oncogene family of transcription factors: potent regulators of hematopoietic cell proliferation and differentiation. , 1994, Seminars in cancer biology.

[6]  W. Kaelin,et al.  E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Nagase,et al.  Delineation of three functional domains of the transcriptional activator encoded by the c-myb protooncogene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H. Werner,et al.  The IGFI receptor gene: A molecular target for disrupted transcription factors , 2003, Genes, chromosomes & cancer.

[9]  Jung Soo Kim,et al.  Induction of apoptosis in K562 cells by dominant negative c-myb. , 2002, Experimental hematology.

[10]  J. Lipsick,et al.  Constitutive expression of full-length c-Myb transforms avian cells characteristic of both the monocytic and granulocytic lineages. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[11]  R. Weinberg,et al.  The role of RB in cell cycle control. , 1995, Progress in cell cycle research.

[12]  R. Watson,et al.  Three genes with different functions in transformation are regulated by c-Myb in myeloid cells. , 2001, Blood cells, molecules & diseases.

[13]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[14]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[15]  T. Graf,et al.  Mutations in v-myb alter the differentiation of myelomonocytic cells transformed by the oncogene , 1990, Cell.

[16]  G. de Murcia,et al.  Importance of Poly(ADP-ribose) Polymerase and Its Cleavage in Apoptosis , 1998, The Journal of Biological Chemistry.

[17]  M. Clarke,et al.  bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. , 1996, Cancer research.

[18]  S. Tóth,et al.  Autocrine and paracrine regulation by cytokines and growth factors in melanoma. , 2000, Cytokine.

[19]  T. Gonda,et al.  Targeting c-Myb expression in human disease , 2003, Expert opinion on therapeutic targets.

[20]  H. Schirrmeister,et al.  Targeting bcl-2 by triplex-forming oligonucleotide--a promising carrier for gene-radiotherapy. , 2003, Cancer biotherapy & radiopharmaceuticals.

[21]  T. Gonda,et al.  DNA binding-independent transcriptional activation of the vascular endothelial growth factor gene (VEGF) by the Myb oncoprotein. , 2006, Biochemical and biophysical research communications.

[22]  K. Weston,et al.  A dominant interfering Myb mutant causes apoptosis in T cells. , 1996, Genes & development.

[23]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[24]  B. Calabretta,et al.  A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. , 1988, Science.

[25]  M. Hagiwara,et al.  Tetracycline-induced expression of an anti-c-Myb single-chain antibody and its inhibitory effect on proliferation of the human leukemia cell line K562 , 2000, Cancer Gene Therapy.

[26]  Wenbiao Liu,et al.  Endothelial cell survival and apoptosis in the tumor vasculature , 2000, Apoptosis.

[27]  Angus Lauder,et al.  c-myb Transcription Is Activated by Protein Kinase B (PKB) following Interleukin 2 Stimulation of T Cells and Is Required for PKB-Mediated Protection from Apoptosis , 2001, Molecular and Cellular Biology.

[28]  R. Eisenman,et al.  New light on Myc and Myb. Part I. Myc. , 1990, Genes & development.

[29]  P. Glazer,et al.  Triplex‐Mediated, in vitro Targeting of Psoralen Photoadducts within the Genome of a Transgenic Mouse , 1996, Photochemistry and photobiology.

[30]  R. Ramsay,et al.  MYB: An old oncoprotein with new roles , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[31]  D. Boettiger,et al.  Developmental regulation of c-myb in normal myeloid progenitor cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.